Papillary necrosis associated with the HIV protease inhibitor indinavir. 2001

J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
Dept. of Internal Medicine II, Erasmus University Medical Center Rotterdam, The Netherlands. dieleman@inw2.azr.nl

The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis. The renal consequences of indinavir-associated nephrotoxicity are uncertain. We report a case of papillary necrosis in a patient treated with indinavir. An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir. She passed a non-solid stone and continued indinavir treatment. Intravenous pyelogram performed 20 months later following an episode of left-sided colicky pain showed right-sided papillary necrosis. Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient. Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis.

UI MeSH Term Description Entries
D007681 Kidney Papillary Necrosis A complication of kidney diseases characterized by cell death involving KIDNEY PAPILLA in the KIDNEY MEDULLA. Damages to this area may hinder the kidney to concentrate urine resulting in POLYURIA. Sloughed off necrotic tissue may block KIDNEY PELVIS or URETER. Necrosis of multiple renal papillae can lead to KIDNEY FAILURE. Renal Papillitis, Necrotizing,Renal Medullary Necrosis,Necrosis, Kidney Papillary,Necrosis, Renal Medullary,Necrotizing Renal Papillitides,Necrotizing Renal Papillitis,Papillary Necrosis, Kidney,Papillitides, Necrotizing Renal,Renal Papillitides, Necrotizing
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
October 1997, Urology,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
November 2000, Teratology,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
April 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
September 2003, European journal of immunology,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
June 2008, Presse medicale (Paris, France : 1983),
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
January 1999, European urology,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
July 2014, Journal of medicinal chemistry,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
October 1998, AIDS (London, England),
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
April 1999, Prescrire international,
J P Dieleman, and M van der Feltz, and C H Bangma, and B H Stricker, and M E van der Ende
February 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Copied contents to your clipboard!